Romosozumab in Postmenopausal Women with Low Bone Mineral DensityMichael R. McClung, Henry G. Bone, Bente Langdahl et al.|New England Journal of Medicine|2014Cited by 1.2k
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group StudyMichael R. McClung, Andreas Grauer, Jacques P. Brown et al.|Journal of Bone and Mineral Research|2018Cited by 237
OP0248 Inhibition of Sclerostin with Romosozumab in Postmenopausal Women with Low Bone Mineral Density: Phase 2 Trial ResultsMichael R. McClung, Henry G. Bone, Andreas Grauer et al.|Annals of the Rheumatic Diseases|2013Cited by 5